0001225208-14-023001.txt : 20141110 0001225208-14-023001.hdr.sgml : 20141110 20141110163624 ACCESSION NUMBER: 0001225208-14-023001 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141110 FILED AS OF DATE: 20141110 DATE AS OF CHANGE: 20141110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co. Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MERCK DRIVE STREET 2: P.O. BOX 100 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889-0100 BUSINESS PHONE: 908-423-1000 MAIL ADDRESS: STREET 1: ONE MERCK DRIVE STREET 2: P.O. BOX 100 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889-0100 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FRAZIER KENNETH C CENTRAL INDEX KEY: 0001181175 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 141209163 MAIL ADDRESS: STREET 1: ONE MERCK DRIVE STREET 2: P.O. BOX 100 CITY: WHITEHOUSE STATION STATE: X1 ZIP: 08889-0100 4 1 doc4.xml X0306 4 2014-11-10 0000310158 Merck & Co. Inc. MRK 0001181175 FRAZIER KENNETH C ONE MERCK DRIVE WHITEHOUSE STATION NJ 08889-0100 1 1 Chairman, President & CEO Common Stock 2014-11-10 4 M 0 9333.0000 35.0900 A 350878.0630 D Common Stock 2014-11-10 4 M 0 3542.0000 31.8400 A 354420.0630 D Common Stock 2014-11-10 4 S 0 10000.0000 57.9784 D 344420.0630 D Common Stock - 401(k) Plan 3519.0523 I By 401(k) Stock Option (right to buy) 31.8400 2014-11-10 4 M 0 3542.0000 0.0000 D 2006-02-25 2015-02-24 Common Stock 3542.0000 14164.0000 D Stock Option (right to buy) 35.0900 2014-11-10 4 M 0 9333.0000 0.0000 D 2007-03-03 2016-03-02 Common Stock 9333.0000 37332.0000 D The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.7100 to $58.2300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Holdings include shares acquired in dividend reinvestment transactions. Includes shares acquired and dividends earned through October 7, 2014, in the Merck U.S. Savings Plan, a 401(k) plan. The option became exercisable in equal installments on 2/25/2006, 2/25/2007 and 2/25/2008. The option became exercisable in equal installments on 3/3/2007, 3/3/2008 and 3/3/2009. Katie Fedosz as Attorney-in-Fact for Kenneth C. Frazier 2014-11-10